Phage Therapy in a Burn Patient Colonized with Extensively Drug-Resistant Pseudomonas aeruginosa Responsible for Relapsing Ventilator-Associated Pneumonia and Bacteriemia - PubMed
Cécile Teney 1 ,
Article ImagesCase Reports
doi: 10.3390/v16071080.
Jean-Charles Poupelin 1 , Thomas Briot 2 , Myrtille Le Bouar 3 , Cindy Fevre 4 , Sophie Brosset 5 , Olivier Martin 1 , Florent Valour 3 6 7 , Tiphaine Roussel-Gaillard 8 , Gilles Leboucher 2 , Florence Ader 3 6 7 , Anne-Claire Lukaszewicz 1 6 , Tristan Ferry 3 6 7 9 ; PHAGEinLYON Clinic Study Group
Affiliations
- PMID: 39066242
- PMCID: PMC11281479
- DOI: 10.3390/v16071080
Case Reports
Phage Therapy in a Burn Patient Colonized with Extensively Drug-Resistant Pseudomonas aeruginosa Responsible for Relapsing Ventilator-Associated Pneumonia and Bacteriemia
Cécile Teney et al. Viruses. .
Abstract
Pseudomonas aeruginosa is one of the main causes of healthcare-associated infection in Europe that increases patient morbidity and mortality. Multi-resistant pathogens are a major public health issue in burn centers. Mortality increases when the initial antibiotic treatment is inappropriate, especially if the patient is infected with P. aeruginosa strains that are resistant to many antibiotics. Phage therapy is an emerging option to treat severe P. aeruginosa infections. It involves using natural viruses called bacteriophages, which have the ability to infect, replicate, and, theoretically, destroy the P. aeruginosa population in an infected patient. We report here the case of a severely burned patient who experienced relapsing ventilator-associated pneumonia associated with skin graft infection and bacteremia due to extensively drug-resistant P. aeruginosa. The patient was successfully treated with personalized nebulized and intravenous phage therapy in combination with immunostimulation (interferon-γ) and last-resort antimicrobial therapy (imipenem-relebactam).
Keywords: ICU; Pseudomonas aeruginosa; antimicrobial resistance; burns; phage therapy; ventilator-associated pneumonia.
Conflict of interest statement
T.F. is the principal investigator of the Phaxiam therapeutics clinical trial PhagoDAIR I; Hospices Civils de Lyon received a research grant for the participation of T.F. in the Pherecydes board (later named Phaxiam). C.F. is an employee of Phaxiam therapeutics. The other authors declare no conflicts of interest.
Figures
Similar articles
-
Jault P, Leclerc T, Jennes S, Pirnay JP, Que YA, Resch G, Rousseau AF, Ravat F, Carsin H, Le Floch R, Schaal JV, Soler C, Fevre C, Arnaud I, Bretaudeau L, Gabard J. Jault P, et al. Lancet Infect Dis. 2019 Jan;19(1):35-45. doi: 10.1016/S1473-3099(18)30482-1. Epub 2018 Oct 3. Lancet Infect Dis. 2019. PMID: 30292481 Clinical Trial.
-
Rational approach in the management of Pseudomonas aeruginosa infections.
Bassetti M, Vena A, Russo A, Croxatto A, Calandra T, Guery B. Bassetti M, et al. Curr Opin Infect Dis. 2018 Dec;31(6):578-586. doi: 10.1097/QCO.0000000000000505. Curr Opin Infect Dis. 2018. PMID: 30299364 Review.
-
Alvi IA, Asif M, Ur Rehman S. Alvi IA, et al. Virus Res. 2021 Jan 15;292:198250. doi: 10.1016/j.virusres.2020.198250. Epub 2020 Nov 28. Virus Res. 2021. PMID: 33259872
-
Gong YL, Yang ZC, Yin SP, Liu MX, Zhang C, Luo XQ, Peng YZ. Gong YL, et al. Zhonghua Shao Shang Za Zhi. 2016 Sep 20;32(9):529-35. doi: 10.3760/cma.j.issn.1009-2587.2016.09.004. Zhonghua Shao Shang Za Zhi. 2016. PMID: 27647068 Chinese.
-
Pseudomonas aeruginosa: evolution of antimicrobial resistance and implications for therapy.
McCarthy K. McCarthy K. Semin Respir Crit Care Med. 2015 Feb;36(1):44-55. doi: 10.1055/s-0034-1396907. Epub 2015 Feb 2. Semin Respir Crit Care Med. 2015. PMID: 25643270 Review.
References
-
- Center for Disease Control and Prevention Pseudomonas Aeruginosa in Healthcare Settings. [(accessed on 1 July 2023)]; Available online: https://www.cdc.gov/hai/organisms/pseudomonas.html.
-
- Kollef M.H., Chastre J., Fagon J.Y., François B., Niederman M.S., Rello J., Torres A., Vincent J.L., Wunderink R.G., Go K.W., et al. Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit. Care Med. 2014;42:2178–2187. doi: 10.1097/CCM.0000000000000510. - DOI - PubMed
-
- American Burn Association National Burn Repository Report of Data from 2006–2015. [(accessed on 5 June 2023)]. Available online: https://ameriburn.org/wp-content/uploads/2017/05/2016abanbr_final_42816.pdf.
Publication types
MeSH terms
Substances
Grants and funding
Access to phage therapy was facilitated by the PHAGE
LYON
program supervised by T.F. and funded by Foundation Hospices Civils de Lyon (https://fondationhcl.fr).
LinkOut - more resources
Full Text Sources
Medical